PGEN
Precigen, Inc.·Healthcare
4.24
0.935%(−0.04)
Market ClosedLast Updated: — ET
52W L: $1.2852W H: $5.47
PGEN NEWS
seekingalpha.com
2d ago
Precigen: Why I Am More Cautious After The Q1 Beat (Downgrade)
Precigen, Inc. delivered $21.6M in Q1 Papzimeos revenue, aligning with bullish expectations but leaving key launch metrics undisclosed. Management projects cash flow breakeven by year-end, but tight cash, high burn, and future margin compression raise execution risk. Papzimeos momentum is positive, yet a lack of patient-level data and potential for pent-up demand clouds true organic growth visibility.
seekingalpha.com
May 14
Precigen: Full Commercial Validation And Room To Run
Precigen is recommended as a buy due to PAPZIMEOS's early FDA approval, its commercial validation, and astonishingly quick insurer and physician adoption. PGEN's AdenoVerse platform underpins near-term growth, with PAPZIMEOS targeting a $2B global RRP market and PRGN-2009 advancing in other HPV-related cancer trials. Management projects a cash flow positive status in 2024, with consensus estimates showing sharply improving EPS and revenue through 2028 and beyond.
marketbeat.com
May 14
Precigen Q1 Earnings Call Highlights
Precigen NASDAQ: PGEN reported a sharp increase in first-quarter 2026 revenue as the company's first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025.
seekingalpha.com
May 13
Precigen, Inc. (PGEN) Q1 2026 Earnings Call Transcript
Precigen, Inc. (PGEN) Q1 2026 Earnings Call Transcript
zacks.com
May 13
Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates
Precigen, Inc. (PGEN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.07 per share a year ago.
prnewswire.com
May 13
Precigen Reports First Quarter 2026 Financial Results and Business Updates
PAPZIMEOS™ launch gaining strong momentum with $21.6 million in net product revenue in the first quarter of 2026 reflecting broad-based uptake across the US Patient hub enrollment continues to gain traction, with approximately 400 patients currently enrolled; a notable 25% of which are from the community setting, underscoring the breadth of PAPZIMEOS's reach and ease of administration Updated durability of response data for PAPZIMEOS will be presented at the upcoming ASCO Annual Meeting RRP Awareness Day will be hosted alongside the Recurrent Respiratory Papillomatosis Foundation on June 11 for the third consecutive year, reflecting the Company's ongoing commitment to the recurrent respiratory papillomatosis (RRP) community The Company continues to advance PRGN-2009 in HPV-associated cancers and plans to provide an AdenoVerse® pipeline update by end of year Cash, cash equivalents, and investments totaled $56.7 million as of March 31, 2026, which together with the anticipated proceeds from PAPZIMEOS revenue, is expected to fund the Company's operations to cash flow break-even by the end of 2026 Conference call scheduled for 4:30 PM ET today GERMANTOWN, Md., May 13, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced first quarter 2026 financial results and business updates.
